Literature DB >> 16550312

Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion.

Shunji Onimaru1, Kazuo Nakamura, Hiroko Kariyazono, Ryuji Ikeda, Takayuki Ueno, Yoshihiro Fukumoto, Akira Yabuki, Ryuzo Sakata, Katsushi Yamada.   

Abstract

We evaluated the effects of edaravone, a hydroxyl radical scavenging agent, on the production of tumor necrosis factor-alpha (TNF-alpha) in myocardium, and the release of TNF-alpha and P-selectin from myocardium after ischemia-reperfusion injury in isolated Langendorff-perfused rat hearts. Cardiodynamic function at stable points during perfusion and 5, 15, 30, and 60 min after the initiation of reperfusion was evaluated by left ventricular developed pressure, rate of increase in left ventricular pressure and rate of decrease in ventricular pressure, coronary flow, and heart rate. At 60 min after the initiation of reperfusion, myocardial infarct size was estimated microscopically using triphenyltetrazolium chloride staining, and expression of TNF-alpha in myocardium was detected by Western blot and immunohistochemistry. At the same time points as the measurement of cardiodynamic function, TNF-alpha and the soluble form of P-selectin in coronary effluent were measured by enzyme immunoassay. At all time points during reperfusion, edaravone markedly improved cardiodynamic function and reduced myocardial infarct size in comparison to the control. In myocardium in the control, TNF-alpha was detected in the endothelial cells and other cells bearing some resemblance to interstitial cells and monocyte cells. Edaravone suppressed this cytokine expression in the corresponding sites. P-selectin as well as TNF-alpha was found in the coronary effluent of the control, and edaravone significantly decreased soluble P-selectin levels in comparison to the control (P < 0.01). Edaravone might have protective effects on cardiac function through reduction of infarct size via decrease of production of TNF-alpha in myocardium induced by ischemia-reperfusion injury and through reduction of the release of adhesion molecules such as P-selectin from vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550312     DOI: 10.1007/s00380-005-0863-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  36 in total

Review 1.  Oxidative stress and cardiac disease.

Authors:  D J Lefer; D N Granger
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

3.  Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation.

Authors:  T Miki; T Miura; A Tsuchida; A Nakano; T Hasegawa; T Fukuma; K Shimamoto
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

Review 4.  Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury.

Authors:  D N Granger
Journal:  Am J Physiol       Date:  1988-12

5.  N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.

Authors:  Y Nishida; S Minatoguchi; M Arai; G Takemura; Y Uno; K Hashimoto; N Wang; X H Chen; T Fujiwara; H Fujiwara
Journal:  Heart Vessels       Date:  2000       Impact factor: 2.037

6.  Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion.

Authors:  B S Cain; D R Meldrum; C A Dinarello; X Meng; A Banerjee; A H Harken
Journal:  J Surg Res       Date:  1998-05       Impact factor: 2.192

7.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).

Authors:  G Torre-Amione; S Kapadia; C Benedict; H Oral; J B Young; D L Mann
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

8.  Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass.

Authors:  N J Jansen; W van Oeveren; Y J Gu; M H van Vliet; L Eijsman; C R Wildevuur
Journal:  Ann Thorac Surg       Date:  1992-10       Impact factor: 4.330

9.  Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart.

Authors:  U Minhaz; M Tanaka; H Tsukamoto; K Watanabe; S Koide; A Shohtsu; H Nakazawa
Journal:  Free Radic Res       Date:  1996-05

10.  The role of inflammation markers in triggering acute coronary events.

Authors:  Mehmet Tokaç; Ali Ozeren; Murad Aktan; Bülent B Altunkeser; Kurtuluş Ozdemir; Akif Düzenli; Hasan Gök
Journal:  Heart Vessels       Date:  2003-09       Impact factor: 2.037

View more
  7 in total

1.  Analysis of heart rate variability as an index of noncardiac surgical stress.

Authors:  Takafumi Ushiyama; Katsufumi Mizushige; Hisao Wakabayashi; Takaaki Nakatsu; Ken Ishimura; Yuka Tsuboi; Hajime Maeta; Yasuyuki Suzuki
Journal:  Heart Vessels       Date:  2008-02-14       Impact factor: 2.037

2.  Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).

Authors:  Kiyoshi Kikuchi; Nobuyuki Takeshige; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Chiemi Kikuchi; Narumi Iida; Hisaaki Uchikado; Naohisa Miyagi; Naoto Shiomi; Terukazu Kuramoto; Ikuro Maruyama; Motohiro Morioka; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-09-20       Impact factor: 2.447

3.  Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart.

Authors:  Kazuhiro Yamazaki; Senri Miwa; Shinya Toyokuni; Shintaro Nemoto; Wnimunk Oriyanhan; Kiyoaki Takaba; Yoshiaki Saji; Akira Marui; Takeshi Nishina; Tadashi Ikeda; Masashi Komeda
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

Review 4.  The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Nobuyuki Takeshige; Munetake Yoshitomi; Motohiro Morioka; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

5.  Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat.

Authors:  Yan Zhang; Yang Yang; Guang-Zhu Zhang; Mou Gao; Guang-Zhi Ge; Qin-Qin Wang; Xin-Chao Ji; Yi-Lin Sun; Hong-Tian Zhang; Ru-Xiang Xu
Journal:  CNS Neurosci Ther       Date:  2016-07-08       Impact factor: 5.243

6.  Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway.

Authors:  Xiaoying Zhao; Erfei Zhang; Xiaofen Ren; Xiaoli Bai; Dongming Wang; Ling Bai; Danlei Luo; Zheng Guo; Qiang Wang; Jianxin Yang
Journal:  Biol Res       Date:  2020-07-03       Impact factor: 5.612

7.  Edaravone attenuates sustained pial arteriolar vasoconstriction independently of endothelial function after unclamping of the abdominal aorta in rabbits.

Authors:  Tomohiro Michino; Kumiko Tanabe; Motoyasu Takenaka; Shigeru Akamatsu; Masayoshi Uchida; Mami Iida; Hiroki Iida
Journal:  Korean J Anesthesiol       Date:  2021-06-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.